Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 [Yahoo! Finance]
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: Yahoo! Finance
On March 20, 2026, Wedbush raised the price target on Larimar Therapeutics, Inc. (NASDAQ:LRMR) to $13 from $12 previously and maintained an Outperform rating. Wedbush said the Q4 update was in line with expectations as the company prepares for its nomlabofusp regulatory submission in June 2026, noting management reiterated a cash runway into Q2 2027 following recent financing, while near-term focus is on updated open-label data expected in Q2. On March 19, 2026, Larimar Therapeutics, Inc. (NASDAQ:LRMR) reported Q4 EPS of (73c), compared to the (55c) consensus estimate. As of December 31, 2025, the company had $136.9M in cash, cash equivalents, and marketable securities, along with $107.6M in net proceeds from a February 2026 public offering, supporting a projected cash runway into Q2 2027. Chief Executive Officer Carole Ben-Maimon said the company is advancing nomlabofusp toward registration, highlighting “Breakthrough Therapy Designation” and ongoing FDA engagement, while noting p
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Larimar Therapeutics (LRMR) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Larimar Therapeutics (LRMR) had its price target raised by Wedbush from $12.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22 [Seeking Alpha]Seeking Alpha
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Larimar Therapeutics to Participate in Upcoming Investor Conferences in MarchGlobeNewswire
LRMR
Earnings
- 3/19/26 - Miss
LRMR
Sec Filings
- 3/19/26 - Form S-8
- 3/19/26 - Form 10-K
- 3/19/26 - Form 8-K
- LRMR's page on the SEC website